Compare SBSI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBSI | DBVT |
|---|---|---|
| Founded | 1960 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 950.3M | 850.9M |
| IPO Year | 1995 | 2014 |
| Metric | SBSI | DBVT |
|---|---|---|
| Price | $31.72 | $9.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $34.00 | ★ $38.55 |
| AVG Volume (30 Days) | 115.2K | ★ 359.2K |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 1.68 | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | $4.65 | N/A |
| Revenue Next Year | $3.15 | $1,630.16 |
| P/E Ratio | $18.86 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $27.59 | $8.63 |
| 52 Week High | $36.20 | $26.19 |
| Indicator | SBSI | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 39.04 |
| Support Level | $31.69 | $8.63 |
| Resistance Level | $33.34 | $12.73 |
| Average True Range (ATR) | 0.54 | 0.44 |
| MACD | 0.21 | 0.13 |
| Stochastic Oscillator | 94.78 | 52.71 |
Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.